Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04572607
Other study ID # 19-FaSPyN-SA-25.TP
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 1, 2019
Est. completion date July 18, 2020

Study information

Verified date October 2020
Source Universidad Autonoma de Nuevo Leon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Thirteen healthy subjects (5 males; 8 females) ages 25-50 years, with BMI (body mass index): <25 kg/m2 completed the study. The participants were selected randomly, either the control group (n= 7) or honey group (n= 6). Subjects of honey group consumed 25 g of honey each day for 4 weeks.


Description:

18 healthy participants (body mass index [BMI] <25 kg/m2) between 25-50 years of age were recruited, of which 13 subjects (male [n=5]) and female [n=8]) completed the study. The participants were allocated randomly either control group (n= 7) or honey group (n= 6). Subjects of honey group consumed 25 g of honey each day for 4 weeks. Participants of both groups did not undergo a special diet regimen, drug therapy, or change in their lifestyle, such as physical exercise, during the period of study. A 3- day food record including two weekdays and one weekend day was used to assess the habitual food intake of the participants prior to initiation of the trial and repeated each week of intervention. Also, dietary intake was calculated using the database Food Processor® (Version. 10.3.0.), including nutritional information of Mexican foods when they weren't on the list.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date July 18, 2020
Est. primary completion date July 12, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 50 Years
Eligibility Inclusion Criteria:

- Male

- Female

- Ages 25-50 years,

- BMI (body mass index): under 25 kg per m2.

Exclusion Criteria:

- Not smoker

- Not have an allergy to honey

- Not pregnant,

- Not been previously diagnosed any disease resulting in metabolic disorders

- Not chronically use medications known to affect metabolism

- Not participate in greater than 3 hours of structured exercise per week.

- Female participants that used some kind of contraceptives

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
The consumption of avocado honey was analyzed
The subjects of honey group consumed 25 g of honey each day for 4 weeks.

Locations

Country Name City State
Mexico Facultad de Salud Publica y Nutricion Monterrey Nuevo Leon

Sponsors (1)

Lead Sponsor Collaborator
Universidad Autonoma de Nuevo Leon

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Subject numbers that experienced a change of glucose level (mg/dL) post-intake of 25 g/day of honey From the start of treatment (baseline) until 4 weeks
Primary Subject numbers that experienced change of triglycerides levels (mg/dL) post-intake of 25 g/day honey From the start of treatment (baseline) until 4 weeks
Primary Subject numbers that experienced change of total cholesterol levels (mg/dL) post-intake of 25 g/day honey From the start of treatment (baseline) until 4 weeks
Primary Subject numbers that experienced change of HDL-cholesterol levels (mg/dL) post-intake of 25 g/day honey From the start of treatment (baseline) until 4 weeks
Primary Subject numbers that experienced change of LDL-cholesterol levels (mg/dL) post-intake of 25 g/day honey From the start of treatment (baseline) until 4 weeks
Primary Subject numbers that experienced change of body weight (kg) post-intake of 25 g/day honey. Frame: from the start of treatment (baseline) until 4 weeks
Primary Subject numbers that experienced change of body fat (%) post-intake of 25 g/day honey From the start of treatment (baseline) until 4 weeks
Primary Subject numbers that experienced change of waist circumference (cm) post-intake of 25 g/day honey From the start of treatment (baseline) until 4 weeks
Primary Subject numbers that experienced change of hip circumference (cm) post-intake of 25 g/day honey From the start of treatment (baseline) until 4 weeks
Primary Subject numbers that experienced change of waist-hip ratio post-intake of 25 g/day honey From the start of treatment (baseline) until 4 weeks
Primary Subject numbers that experienced change of BMI (weight (kg)/height (m)2) post-intake of 25 g/day honey From the start of treatment (baseline) until 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1